Y-27632 dihydrochloride: Selective ROCK Inhibitor for Rho/ROCK Pathway Studies

Executive Summary: Y-27632 dihydrochloride is a highly selective, cell-permeable inhibitor of ROCK1 and ROCK2, with an IC₅₀ of ~140 nM for ROCK1 and a K_i of 300 nM for ROCK2, showing >200-fold selectivity over other kinases (APExBIO). It modulates cytoskeletal organization by disrupting Rho-mediated stress fiber formation and impedes cell cycle progression from G1 to S phase (Ni et al., 2023). Y-27632 displays robust solubility in DMSO, ethanol, and water, and is stable for months at -20°C. The compound has been validated in multiple in vitro and in vivo models for reducing cell proliferation and suppressing tumor invasion. APExBIO supplies this product (SKU A3008) for translational research in cell biology, cancer, and regenerative medicine.

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases central to cytoskeletal regulation, cell adhesion, migration, and contractility. Dysregulation of the Rho/ROCK pathway contributes to pathological processes including cancer progression, fibrosis, and neurodevelopmental disorders (Ni et al., 2023). Inhibition of ROCK signaling can modulate cell cycle checkpoints, reduce cellular stress fiber formation, and affect cytokinesis. Y-27632 dihydrochloride was developed to selectively inhibit ROCK activity, offering a precise tool for dissecting Rho/ROCK-mediated cellular processes. Selective inhibition is crucial, as off-target effects from broader kinase inhibition can confound experimental outcomes.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride competitively binds to the ATP-binding pocket of the catalytic domains of ROCK1 and ROCK2. This interaction blocks kinase activity and downstream phosphorylation of myosin light chain (MLC) and LIM kinase, leading to decreased actin-myosin contractility and disruption of stress fibers (First-Strand-cDNA.com). The compound exhibits an IC₅₀ of approximately 140 nM for ROCK1 and a K_i of 300 nM for ROCK2. Selectivity is >200-fold relative to other kinases, including protein kinase C (PKC), cAMP-dependent protein kinase (PKA), myosin light chain kinase (MLCK), and p21-activated kinase (PAK). Disruption of Rho/ROCK signaling by Y-27632 leads to: (i) reduced formation of actin stress fibers, (ii) inhibition of cell cycle progression (G1/S), and (iii) impaired cytokinesis. These effects are foundational for its application in stem cell maintenance, cancer invasion studies, and cytoskeletal research.

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC₅₀ of ~140 nM and ROCK2 with a K_i of 300 nM under standard in vitro kinase assay conditions (APExBIO product data).
• Shows >200-fold selectivity over PKC, PKA, MLCK, and PAK in enzymatic panels (APExBIO, product page).
• Reduces stress fiber formation in cultured cells within 1 hour at 10 μM concentration (Ni et al., 2023).
• Suppresses proliferation of prostatic smooth muscle cells in vitro in a dose-dependent manner between 0.3–30 μM (APExBIO; see First-Strand-cDNA.com).
• In vivo, reduces tumor invasion and metastasis in mouse models of cancer at 10 mg/kg/day, administered intraperitoneally for up to 21 days (Ni et al., 2023).
• Enhances survival and proliferation of human pluripotent stem cells during cell passaging and single-cell dissociation (see PD-L1.com; this article details protocol optimization, while our review details mechanistic benchmarks and translational limits).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is used for:

• Modulating Rho/ROCK signaling in cytoskeletal studies.
• Supporting stem cell viability and clonal expansion.
• Inhibiting tumor invasion and metastasis in preclinical models.
• Improving reproducibility in cell proliferation and cytotoxicity assays.
• Dissecting cytokinesis and cell cycle checkpoint mechanisms.

Its high selectivity reduces off-target effects, making it suitable for advanced biological models. However, some misconceptions and limitations persist.

Common Pitfalls or Misconceptions

• Y-27632 does not inhibit all kinases equally; activity is highly selective for ROCK1/2 and minimal for unrelated kinases such as PKA or PKC (APExBIO).
• It does not reverse established cytoskeletal damage in non-viable cells; it acts only on live, responsive cells.
• Long-term storage of working solutions (>1 week), especially at 4°C, is not recommended due to potential compound degradation.
• Y-27632 is not a substitute for genetic knockout of ROCK1/2; it provides reversible, dose-dependent inhibition.
• Sole use of Y-27632 will not comprehensively model all aspects of Rho/ROCK pathway dysfunction, especially in multi-factorial diseases.

Workflow Integration & Parameters

Y-27632 dihydrochloride (SKU A3008, APExBIO) is supplied as a solid and should be stored desiccated at 4°C or below. For solution preparation:

• Dissolve at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water.
• Warm to 37°C or use an ultrasonic bath to enhance solubility.
• Stock solutions may be stored at -20°C for several months; avoid repeated freeze-thaw cycles.
• For in vitro assays, typical working concentrations range from 1–30 μM.
• In vivo protocols often use 10 mg/kg/day (i.p.), but dosing should be optimized per model.

Researchers should validate compound activity in their specific cell type and assay conditions. For troubleshooting and protocol enhancements, see Optimizing Cell Viability and Assay Reproducibility with Y-27632 (this article expands on assay robustness and practical integration).

Conclusion & Outlook

Y-27632 dihydrochloride from APExBIO is a validated, selective ROCK1/2 inhibitor that enables precise modulation of the Rho/ROCK signaling pathway in cytoskeletal, stem cell, and cancer research. Its robust selectivity and favorable solubility profile support reproducible, high-impact studies. Continued development of pathway-specific inhibitors like Y-27632 will advance mechanistic research and therapeutic discovery in cytoskeletal dynamics, regenerative medicine, and oncology. For further insights on strategic translational applications, see Strategic ROCK Inhibition in Translational Research (contrasts emerging clinical perspectives versus the present mechanistic overview).